Defendant

A Punishment of 9,00,000 won, Defendant B’s imprisonment with prison labor and fine of 8,000,000 won, Defendant C’s imprisonment with prison labor for six months and six months.

Punishment of the crime

Defendant

B From around 209, from around 2007, Defendant C, as a full-time member of the Health Insurance Review Evaluation Committee under the Health Insurance Review Evaluation Institute (hereinafter “Health Welfare Review Committee”), has been in charge of consulting on the verification of eligibility for medical care benefits and on the evaluation of adequacy of medical care benefits related to the prescription when providing medical treatment. In particular, Defendant B, while working as a member of the Medical Care Benefits Evaluation Committee (hereinafter “Committee”), was in progress from around 2007, from around 2007 to around 2012, pursuant to the “Plan on the Maintenance of Registered Medicines” (the above plan was implemented from around 2007 to around 2012 according to the public notice of the Health and Welfare Department, after reviewing data on the determination of the clinical usefulness of the pharmaceutical benefits, after evaluating the appropriateness of the insurance benefits for the pharmaceutical products, was in charge of determining the appropriateness of the insurance benefits exemption or the reduction of the insurance benefits, etc., based on clinical data related to the safety and efficacy of the pharmaceutical products.

Defendant B, as Defendant A’s high school line, was aware of the fact that Defendant B and Defendant A had a long-standing friendship at a group of persons engaged in the medicine industry among the same school origin, and Defendant C and Defendant A had a long-standing friendship as the motive for the pharmacy of N University.

1. The committee where Defendant B belongs selected “other fire-fighting machine medicine” as a medicine subject to examination in around 2011, and decided “M” as a medicine specializing in treatment of liver diseases manufactured and sold by L as “other drug excluded from benefits” on February 15, 201 due to lack of clinical data around February 15, 201, and maintained the benefit on the condition that it additionally submits clinical data through a review on April 21, 201 upon receipt of L’s objection.